Pulmonary toxicity after intraperitoneal mitomycin C: a case report of a rare complication of HIPEC.
World J Surg Oncol
; 15(1): 49, 2017 Feb 20.
Article
in En
| MEDLINE
| ID: mdl-28219391
BACKGROUND: Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) has become a common treatment approach for disseminated appendiceal neoplasms. Systemic absorption of intraperitoneal chemotherapeutics may lead to drug-induced toxicity, most commonly neutropenia. Mitomycin C has been the most commonly used chemotherapeutic in HIPEC for the past several decades. CASE PRESENTATION: Here, we describe a rare pulmonary complication secondary to intraperitoneal administration of mitomycin C. CONCLUSIONS: While rare, intraperitoneal mitomycin C has the potential to cause serious pulmonary toxicity that should be considered with administration. To our knowledge, this report represents only the second case described in the literature.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Appendiceal Neoplasms
/
Peritoneal Neoplasms
/
Respiratory Distress Syndrome
/
Mitomycin
/
Combined Modality Therapy
Limits:
Adult
/
Female
/
Humans
Language:
En
Journal:
World J Surg Oncol
Year:
2017
Document type:
Article
Affiliation country:
United States
Country of publication:
United kingdom